Related Experiment Videos
Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease
Taek Jin Lee1, Ki Hwan Kim, Jin-Kyong Chun
1Department of Pediatrics, College of Medicine, Pochon CHA University, Seongnam, Korea.
Purpose:
The aim of this study was to evaluate the efficacy of low-dose oral methotrexate (MTX) as a treatment for patients with Kawasaki disease (KD) which was resistant to intravenous immunoglobulin (IVIG).
Patients And Methods:
The patients who had persistent or recrudescent fever after treatment with IVIG were subsequently treated with low-dose oral MTX [10mg/body surface area (BSA)] once weekly.
Results:
Seventeen patients developed persistent or recrudescent fever after treatment of KD with IVIG and were consequently given MTX. The proportion of children with coronary artery lesions (CALs) was 76%. The median value of maximum body temperatures decreased significantly within 24 hours of MTX therapy (38.6 degrees C vs. 37.0 degrees C, p < 0.001). The median CRP (C-reactive protein) level was found to be significantly lower 1 week after administering the first dose of MTX (8.9mg/dL vs. 1.2mg/dL, p < 0.001). The median duration of fever before MTX treatment was shorter in CALs (-) group than in CALs (+) group (7 days vs. 10 days, p = 0.023). No adverse effects of MTX were observed.
Conclusion:
MTX treatment for IVIG-resistant KD resulted in quick resolution of fever and rapid improvement of inflammation markers without causing any adverse effects. MTX therapy should further be assessed in a multicenter, placebo-blinded trial to evaluate whether it also improves coronary artery outcome.
Insights
Low-dose oral methotrexate (MTX) effectively treated Kawasaki disease (KD) resistant to intravenous immunoglobulin (IVIG), rapidly reducing fever and inflammation markers without adverse effects.
Area of Science:
- Pediatric Rheumatology
- Immunology
- Pharmacology
Background:
- Kawasaki disease (KD) is a critical pediatric vasculitis.
- Intravenous immunoglobulin (IVIG) is the standard treatment, but some patients exhibit resistance.
- Persistent fever and inflammation indicate treatment failure and risk of coronary artery lesions (CALs).
Purpose of the Study:
- To evaluate the efficacy of low-dose oral methotrexate (MTX) in patients with IVIG-resistant Kawasaki disease (KD).
Main Methods:
- Patients with persistent or recurrent fever post-IVIG received low-dose oral MTX (10mg/BSA) weekly.
- Clinical and laboratory parameters, including fever duration, body temperature, and C-reactive protein (CRP) levels, were monitored.
- The incidence of coronary artery lesions (CALs) was assessed.
Main Results:
- Seventeen patients with IVIG-resistant KD were treated with MTX.
- MTX therapy led to a significant decrease in median body temperature within 24 hours (38.6°C vs. 37.0°C).
- Median CRP levels significantly reduced one week after MTX initiation (8.9mg/dL vs. 1.2mg/dL), with no observed adverse effects.
Conclusions:
- Low-dose oral MTX is effective in rapidly resolving fever and improving inflammatory markers in IVIG-resistant KD.
- MTX demonstrates a favorable safety profile in this patient cohort.
- Further multicenter, placebo-blinded trials are warranted to confirm MTX's impact on coronary artery outcomes.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Rheumatic Heart Disease III: Medical Management
Myocarditis III: Medical Management
Endocarditis III: Medical Management
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...